GFGuosheng Fu

Guosheng Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guosheng Fu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Zheng

    Department of Cardiovascular Diseases, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, PR China

    4 shared publications
  • Wenbin Zhang

    Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

    3 shared publications
  • Ying Yang

    Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China

    3 shared publications
  • Fen Xu

    Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Zhejiang, Hangzhou, China

    2 shared publications
  • Fuyu Qiu

    Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China

    2 shared publications
  • He Huang

    Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

    2 shared publications

Latest Publications

  • 冠状动脉CT血管造影提示临界病变有易损斑块患者预后分析

    by Zhanlu Li, He Huang, Wenbin Zhang, Min Wang, Guosheng Fu

    分析冠状动脉CT血管造影(CCTA)提示临界病变含有易损斑块患者的预后。 回顾性分析2015年2月2日至9月13日在浙江大学医学院附属邵逸夫医院行CCTA检查提示为临界病变(直径狭窄50%~70%)且不需要介入治疗的患者1963例(2728处病变)。根据CCTA提示的斑块性质分为易损斑块组(804例)和稳定斑块组(1159例)。以发生主要不良心血管事件(MACE,包括心源性死亡、非致死性急性心肌梗死及靶病变血运重建)为观察终点,比较两组的预后。 平均随访(27.4±2.3)个月,易损斑块组MACE发生率高于稳定斑块组(分别为10.8%和2.3%, P < 0.01),调整年龄、性别、吸烟、高血压病、糖尿病、高脂血症等进行多因素分析显示,易损斑块组发生MACE的风险比( HR)为5.022(95% CI:3.254~7.751, P < 0.01)。亚组分析提示,易损斑块未服药组(服用抗血小板及他汀类药物3个月及以下)和易损斑块服药组(服用抗血小板及他汀类药物3个月以上)MACE发生率分别为17.0%和5.8%,易损斑块未服药组发生MACE的风险增加( HR=3.149,95% CI:1.987~4.992, P < 0.01);而稳定斑块组未观察到此差异( HR=1.721,95% CI:0.798~3.712, P>0.05)。 CCTA提示临界病变含有易损斑块的患者危险性更高,而药物治疗主要作用于易损斑块,对稳定斑块是否有效有待进一步讨论。

  • Open Access

    Early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF): study protocol for an open-label registry-based prospective clinical trial

    by Ying Yang, Chao Shen, Jiangting Lu, Fen Xu, Jinshan Tong, Jiangfen Jiang, Guosheng Fu

    Background: Conventional pharmacologic therapies aim to reduce fluid overload in advanced heart failure (HF) represented by intravenous (IV) loop diuretics (LDs) have sometimes not so efficacious and been reported to have side effects such as unpredictable removal of water and sodium and electrolyte disturbance. It is not certain whether early ultrafiltration (UF) is effective than LDs in relieving edema. Given the weakness of evidence for early UF in patients with fluid overload, recommendations of UF in guidelines is considered as second-line therapy only for patients with refractory congestion, who failed to respond to LD-based strategies. Methods: The early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF) trial is an open-label, registry-based, prospective study, recruiting patients with severe acute decompensated HF who are hospitalized for HF worsening due to overt fluid overload 24 h from hospital admission. Forty patients will be enrolled to two treatment groups (n = 20 for each group). The primary outcomes are the changes of weight loss and dyspnea severity score after treatment, as well as the occurrence of clinically overt major bleeding. Discussion: EUC-CHF trial was primarily designed to evaluate the efficacy and safety of early UF in patients with acute decompensated HF to reduce volume overload and improve clinical outcome. The trial aims to determine if early UF in acute HF is superior to IV LDs in clinical parameter improvement without adverse events and prevents rehospitalization up to 30 days. Also the trial is expected to establish a scoring system based on Chinese population to guide early UF treatment in appropriate patients. EUC-CHF is one of the first controlled trials tailored to determine the benefit of UF with 24 h from hospital admission. Trial registration: www.chictr.org.cn, ChiCTR1800019556. Registered on 18 November 2018.


  • Open Access

    Thymosin β4 promotes glucose‑impaired endothelial progenitor cell function via Akt/endothelial nitric oxide synthesis signaling pathway

    by Fuyu Qiu, Jiale Song, Xukun Bi, Meihui Wang, Yanbo Zhao, Guosheng Fu

    Circulating endothelial progenitor cells (EPCs) are a subtype of hematopoietic stem cells, which can differentiate into endothelial cells and restore endothelial function. However, high glucose decreases the number and impairs the function of EPCs. A previous study showed that thymosin β4 (Tβ4), a pleiotropic peptide beneficial for multiple functions of various types of cells, could promote EPC migration and dose‑dependently upregulate the phosphorylation of Akt and endothelial nitric oxide synthesis signaling (eNOS). In present study, the hypothesis that Tβ4 can improve glucose‑suppressed EPC functions via the Akt/eNOS signaling pathway and restores the production of nitric oxide (NO) is investigated. EPCs were isolated from the peripheral blood of healthy volunteers and formed a cobblestone shape after 3‑4 weeks of cultivation. Then, EPCs were treated with high concentrations of glucose (25 mM) for 4 days and administrated with Tβ4 for further study. Transwell migration and tube formation assays were performed to access the migratory and angiogenic ability of EPCs. In addition, the quantity of Akt, eNOS and the concentration of nitric oxide (NO) was investigated. Functional studies showed that high concentrations of glucose significantly suppressed EPC function, while this adverse effect was reversed by the administration of Tβ4. In addition, Akt small interfering (si)RNA and eNOS siRNA were demonstrated to reduce the protective effect of Tβ4 against glucose‑impaired EPC functions. These findings suggest that Tβ4 improves glucose‑impaired EPC functions via the Akt/eNOS signaling pathway.


  • Rationale and Design of the Evaluation of Oral Anticoagulation for Reduction of Thrombo-embolism in Chinese Patients with Device-Detected Subclinical Atrial Fibrillation (ART-CAF) Trial: an Open-Label Registry-Based Clinical Trial

    by Ying Yang, Fen Xu, Jinshan Tong, Leyan Cai, Wenbing Jiang, Xia Sheng, Yiwen Pan, Jiangfen Jiang, Jiefang Zhang, Dongmei Jiang, et al.

    Subclinical atrial fibrillation (AF) was found in a large number of pacemaker patients. It is not certain whether there is a similar risk/benefit ratio for oral anticoagulation in patients with subclinical AF compared to patients with similar risk profiles and clinically diagnosed AF. Given the weakness of clinical evidence for oral anticoagulation in patients with device-detected subclinical AF, specific recommendations in most guidelines for this population are scarce and rarely similar.


  • Inhibition of mevalonate pathway prevents ischemia‐induced cardiac dysfunction in rats via RhoA‐independent signaling pathway

    by Ying Yang, Xiqing Rong, Xue Lv, Wenbing Jiang, Yuan Yang, Dongwu Lai, Shiming Xu, Guosheng Fu

    Summary: Aim: We previously demonstrated that anoxia‐mediated Ca2+ handling dysfunction could be ameliorated through inhibition of mevalonate pathway via RhoA‐ and Ras‐related mechanisms in H9c2 cells. In this study, we further explored whether inhibition of mevalonate pathway is associated with cardiac remodeling and dysfunction in ischemic cardiomyopathy, and discussed the possible role of Ras, Rac and RhoA in cardiac dysfunction.Methods: We investigated the role of mevalonate pathway in cardiac remodeling and cardiomyocyte Ca2+ handling proteins expression in a rat model of cardiac dysfunction due to myocardial infarction (MI). After MI, adult male Sprague‐Dawley rats were treated with drugs that antagonize key components in mevalonate pathway, including 3‐hydroxy‐3‐methylglutaryl‐CoA reductase, farnesyl pyrophosphate synthase, and Rho‐kinase for 10 weeks. The protein expression of ryanodine receptor 2 (RyR2), sarcoplasmic reticulum Ca2+ ATPase (SERCA) 2a, phospholamban (PLB), phospho‐PLB at serine‐16 (PSer16‐PLB), FKBP12.6, and RhoA as well as RyR2 and FKBP12.6 mRNA levels was evaluated.Results: Rosuvastatin and alendronate treatment prevented myocardial remodeling, improved cardiac function and reduced infarct size. Furthermore, rosuvastatin and alendronate promoted an increase in the protein expression of SERCA2a and PSer16‐PLB/PLB ratio as well as partially restored the RyR2 and FKBP12.6 gene and protein expression. Fasudil failed to exert these beneficial effects.Conclusions: These findings indicate that mevalonate pathway inhibition by rosuvastatin and alendronate prevents cardiac remodeling and dysfunction possibly through RhoA‐independent mechanisms.


  • The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study

    by Wenbin Zhang, Yi Luan, Chongying Jin, Shengjie Xu, Xukun Bi, Yanbo Zhao, Fuyu Qiu, Guosheng Fu, Min Wang

    Introduction More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. Methods One hundred and twenty-two CAD patients with type 2 diabetes with confirmed coronary artery calcification (CAC) will be recruited consecutively in a 12-month period. These patients will receive rosuvastatin (20 mg/day) therapy in the next 24 months. Blood tests and adverse events will be collected at routine follow-up of 1, 3, 6, 12, 18 and 24 months. The primary endpoint will be the change of CAC density score measured by coronary CT angiography after 24 months’ treatment of rosuvastatin (20 mg/day) compared with baseline. The secondary endpoints will be the change of serum sclerostin and the effect on the volume score of CAC in those patients. Results We expect that rosuvastatin could both increase the density of CAC to improve plaque stability and up-regulate serum sclerostin, which would suggest the underlying mechanism of the plaque stabilization by a statin. Conclusion This study would be the first to demonstrate the impact of rosuvastatin on the density score of coronary artery calcification in CAD patients with type 2 diabetes. This study has been registered in ClinicalTrials.gov (NCT02418884).


  • Open Access

    Aliskiren‐attenuated myocardium apoptosis via regulation of autophagy and connexin‐43 in aged spontaneously hypertensive rats

    by Wenbin Zhang, Gang Zhao, Xiaona Hu, Min Wang, Hua Li, Yong Ye, Qijun Du, Jin Yao, Zhijun Bao, Wei Hong, et al.

    There are controversies about the mechanism of myocardium apoptosis in hypertensive heart disease. The aim of this study was to investigate the relationship among autophagy, Cx43 and apoptosis in aged spontaneously hypertensive rats (SHRs) and establish whether Aliskiren is effective or not for the treatment of myocardium apoptosis. Twenty‐one SHRs aged 52 weeks were randomly divided into three groups, the first two receiving Aliskiren at a dose of 10 and 25 mg/kg/day respectively; the third, placebo for comparison with seven Wistar‐Kyoto (WKY) as controls. After a 2‐month treatment, systolic blood pressure (SBP), heart to bw ratios (HW/BW%) and angiotensin II (AngII) concentration were significantly enhanced in SHRs respectively. Apoptotic cardiomyocytes detected with TUNEL and immunofluorescent labelling for active caspase‐3 increased nearly fourfolds in SHRs, with a decline in the expression of survivin and AKT activation, and an increase in caspase‐3 activation and the ratio of Bax/Bcl‐2. Myocardium autophagy, detected with immunofluorescent labelling for LC3‐II, increased nearly threefolds in SHRs, with the up‐regulation of Atg5, Atg16L1, Beclin‐1 and LC3‐II. The expression of Cx43 plaque was found to be down‐regulated in SHRs. Aliskiren significantly reduced SBP, HW/BW%, AngII concentration and the expression of AT1R. Thus, Aliskiren protects myocardium against apoptosis by decreasing autophagy, up‐regulating Cx43. These effects showed a dose‐dependent tendency, but no significance. In conclusion, the myocardium apoptosis developed during the hypertensive end‐stage of SHRs could be ameliorated by Aliskiren via the regulation of myocardium autophagy and maladaptive remodelling of Cx43.


  • Stromal cell‐derived factor 1α reduces senescence of endothelial progenitor subpopulation in lectin‐binding and DiLDL‐uptaking cell through telomerase activation and telomere elongation

    by Hao Zheng, Cheng‐Ji Shen, Fu‐Yu Qiu, Yan‐Bo Zhao, Guo‐Sheng Fu

    Recent studies have suggested that reduced endothelial progenitor subpopulation in lectin‐binding and DiLDL‐uptaking cell (EPC subpopulation) number and activity was associated with EPC subpopulation senescence that involved telomerase activity and telomere length. Stromal cell‐derived factor‐1α (SDF‐1α) has been shown to augment a variety of cellular functions of EPC subpopulation and subsequently contribute to ischemic neovascularization. Therefore, we investigated whether SDF‐1α might be able to prevent senescence of EPC subpopulation and also investigated the effects of SDF‐1α on the telomerase activity and telomere length. EPC subpopulation were isolated from peripheral blood and characterized. After ex vivo prolonged cultivation, EPC subpopulation became senescent as determined by acidic β‐galactosidase staining. SDF‐1α dose‐dependently inhibited the onset of EPC subpopulation senescence. Moreover, SDF‐1α increased proliferation and colony‐forming activity of EPC subpopulation. SDF‐1α also increased telomerase activity and telomere length, which was accompanied with upregulation of the catalytic subunit, telomerase reverse transcriptase (TERT). Whereas these effects of SDF‐1α on telomerase activity and expression of hTERT mRNA were significantly attenuated by CXCR4‐specific peptide antagonist (AMD3100) and phosphoinositide 3‐kinase (PI3K) inhibitor (LY294002). In conclusions, SDF‐1α delays the onset of EPC subpopulation senescence, which may be related to the activation of telomerase and elongation of telomere length. The inhibition of EPC subpopulation senescence and induction of EPC subpopulation proliferation by SDF‐1α in vitro may importantly improve the functional activity of EPC subpopulation for potential cell therapy. J. Cell. Physiol. 223:757–763, 2010.


  • Early Detection of Pulmonary Vein Reconnection After Isolation in Patients With Paroxysmal Atrial Fibrillation: A Comparison of ATP‐Induction and Reassessment at 30 Minutes Postisolation

    by Chen‐Yang Jiang, Ru‐Hong Jiang, Seiichiro Matsuo, Qiang Liu, You‐Qi Fan, Zhu‐Wen Zhang, Guo‐Sheng Fu

    Introduction: Catheter ablation for paroxysmal AF (PAF) is limited by an unacceptable recurrence rate, mainly due to pulmonary vein (PV) reconnection. Strategies to minimize reconnection include adenosine infusion and also a waiting period of 30 minutes after PV isolation. The aim of the present study was to assess whether these two strategies revealed the same conduction gap. Methods and Results: In total, 88 consecutive patients (54 males, mean age of 60 years) with drug refractory PAF underwent circumferential PV isolation (CPVI). After isolation of ipsilateral PVs, with entry and exit block checked using a circular mapping catheter, 20 mg ATP was injected during isoproterenol infusion to reveal dormant conduction gap(s). Unless the reconnection revealed by ATP persisted, PVs were further remapped with the circular mapping catheter at 30 minutes postisolation. Totally, PV reconnection was observed in 56 (64%) patients. 24.3% veins (80/329) were found reconnected. Reassessment at 30 minutes postablation was more efficient as compared to ATP induction (19.8% vs 14.6% for ATP). The agreement between these 2 methods is moderate (kappa value = 0.50). In veins that transiently reconnected after ATP administration and later observed at 30 minutes postablation, 94% (17 of 19) of them were found being reconnected with the same gap. Conclusion: Acute PV reconnection is common, occurring in 64% of patients, as detected by adenosine infusion and waiting time. Each shows a unique quality as compared to one another. The combined use of these 2 methods may reduce the AF recurrence rate after CPVI.


  • Thymosin β4 Induces Endothelial Progenitor Cell Migration via PI3K/Akt/eNOS Signal Transduction Pathway

    by Fu-Yu Qiu, Xiao-Xiao Song, Hao Zheng, Yan-Bo Zhao, Guo-Sheng Fu

    Thymosin β4, a G-actin-sequestering peptide, has been shown to play an important role in cell migration. However, little is known about the effect of thymosin β4 on circulating endothelial progenitor cell (EPC) directional migration, which is essential for EPC-mediated reendothelialization and neovascularization. In our study, using a transwell migration assay, we showed that thymosin β4 induced EPC migration in a concentration-dependent manner. Western blot analysis revealed that treatment of EPCs with thymosin β4 resulted in a time and concentration-dependent phosphorylation of Akt, endothelial nitric oxide synthase (eNOS), and extracellular signal-regulated kinase (ERK)1/2. Functional analysis showed that thymosin β4-induced EPC migration was blocked by phosphatidylinositol 3-kinase inhibitors (LY294002 or wortmannin) or eNOS inhibitor (Nω-nitro-L-arginine methyl ester) but was not significantly attenuated by mitogen-activated protein kinase (MAPK)/ERK inhibitor (PD98059). These findings suggest that thymosin β4 stimulates EPC directional migration via phosphatidylinositol 3-kinase/Akt/eNOS, rather than via MAPK/ERK signal transduction pathway.